← Back to Search

[18F]AV-1451 for Alzheimer's Disease

Phase 2
Waitlist Available
Led By Denise Park, PhD
Research Sponsored by Neil M Rofsky, MD, MHA
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1-year post study completion
Awards & highlights

Study Summary

This trial will use tau positron emission tomography (PET) scans to study tau deposition in adults of different ages and how it relates to cognition and amyloid deposition.

Eligible Conditions
  • Alzheimer's Disease
  • Cognitive Decline

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1-year post study completion
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1-year post study completion for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Standardized Uptake Value Ratios (SUVrs) Calculated From [18F]AV-1451 PET Scans
Secondary outcome measures
Relationship of Amyloid Accumulation to Tau Burden
Relationship of Tau Burden to Cortical Thickness
Relationship of Tau Burden to Episodic Memory Function
+8 more

Side effects data

From 2022 Phase 2 trial • 125 Patients • NCT04080544
7%
Elevated blood pressure
1%
Black dot in visual field
1%
Muscle soreness in injection arm
1%
Neck rash
1%
Diarrhea, drowsiness, nausea
100%
80%
60%
40%
20%
0%
Study treatment Arm
Follow up DLBS Participants

Trial Design

1Treatment groups
Experimental Treatment
Group I: Follow up DLBS participantsExperimental Treatment2 Interventions
Eight to ten year follow-up DLBS participants who were cognitively normal at the time of enrollment from 2008 to 2014.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
[18F]AV-1451
2019
Completed Phase 2
~130
Positron Emission Tomography
2008
Completed Phase 2
~2240

Find a Location

Who is running the clinical trial?

Neil M Rofsky, MD, MHALead Sponsor
1 Previous Clinical Trials
80 Total Patients Enrolled
Denise Park, PhDPrincipal InvestigatorUniversity of Texas at Dallas
1 Previous Clinical Trials
50 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Acta NeuropathologicaJournal
Neuropathological Stageing of Alzheimer-related Changes
Braak, H., and E. Braak. 1991. “Neuropathological Stageing of Alzheimer-related Changes”. Acta Neuropathologica. Springer Science and Business Media LLC. doi:10.1007/bf00308809.
clinicaltrials.govStudy
Cognitive Decline and Alzheimer's Disease in the Dallas Lifespan Brain Study
Neil M Rofsky, MD, MHA 2019. "Cognitive Decline and Alzheimer's Disease in the Dallas Lifespan Brain Study". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04080544.
~20 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top